The Impact on Hepatic Recurrence After Adjuvant Chemotherapy With Intraarterial Infusion of Idarubicin-Lipiodol

NCT04178642 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped no participants enrolled

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: percutaneous destruction of the tumor + Idarubicin-Lipiodol treatment
PROCEDURE: Percutaneous destruction of the tumor

Sponsor

University Hospital, Montpellier